Free Trial

Zura Bio (ZURA) 10K Form and Latest SEC Filings 2026

Zura Bio logo
$4.80 +0.05 (+1.05%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$5.00 +0.20 (+4.17%)
As of 05:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Zura Bio SEC Filings & Recent Activity

Zura Bio (NASDAQ:ZURA) has submitted 299+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form SCHEDULE 13G/A submitted on May 12, 2026.

Form 4
Zura Bio Ltd Reports Ownership Change on Apr. 2, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Zura Bio Files Current Report on May. 7, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-Q
Zura Bio Files Quarterly Report on May. 7, 2026

The 10-Q contains Zura Bio's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Zura Bio SEC Filing History

Browse Zura Bio's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/12/2026 5:15 PM
SUVRETTA CAPITAL MANAGEMENT, LLC (1569064) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
05/07/2026 6:34 AM
Zura Bio (1855644) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/07/2026 6:35 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2026 1:00 PM
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
04/30/2026 3:17 PM
Zura Bio (1855644) Filer
Form ARS
04/23/2026 3:50 PM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/02/2026 5:00 PM
Kulkarni Sandeep Chidambar (1945691) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 5:00 PM
Davis Kim (1965590) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 5:00 PM
Hyllengren Eric J (1966926) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 5:00 PM
Nistala Kiran (2003539) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 5:00 PM
Whale Gary (1965860) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/19/2026 3:10 PM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/19/2026 3:11 PM
Zura Bio (1855644) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/10/2026 5:40 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 5:30 PM
Nirula Ajay (2116832) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 5:29 PM
Nirula Ajay (2116832) Reporting
Zura Bio (1855644) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/05/2026 6:00 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/02/2026 4:55 PM
Access Industries Holdings LLC (1391297) Reporting
ACCESS INDUSTRIES MANAGEMENT, LLC (1508226) Reporting
AI Biotechnology LLC (1942670) Reporting
Blavatnik Len (1326628) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 4:53 PM
AI Biotechnology LLC (1942670) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13D/A
02/26/2026 7:42 AM
Zura Bio (1855644) Filer
Form 8-K/A
02/24/2026 8:12 PM
Eisner Mark (1834161) Reporting
Zura Bio (1855644) Issuer
Form 3
Initial statement of beneficial ownership of securities  
02/24/2026 8:14 PM
Eisner Mark (1834161) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/24/2026 3:29 PM
Zura Bio (1855644) Filer
Form 424B5
02/23/2026 5:40 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/13/2026 3:46 PM
SUVRETTA CAPITAL MANAGEMENT, LLC (1569064) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
02/11/2026 5:02 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/27/2026 5:44 PM
Thiara Parvinder (1995535) Reporting
Zura Bio (1855644) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/27/2026 5:45 PM
Thiara Parvinder (1995535) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2026 4:56 PM
Kulkarni Sandeep Chidambar (1945691) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 5:45 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 5:27 PM
Athanor Capital (2101709) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G
01/02/2026 5:19 PM
Athanor Capital (2101709) Reporting
UGS Capital LLC (2079932) Reporting
Zura Bio (1855644) Issuer
Form 3
Initial statement of beneficial ownership of securities  
01/02/2026 3:19 PM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/17/2025 7:00 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 7:25 AM
Deep Track Capital, LP (1856083) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
11/13/2025 5:30 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 5:32 AM
Zura Bio (1855644) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/10/2025 7:20 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/04/2025 5:32 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2025 6:03 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 4:52 PM
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
Your book is inside (Ad)

The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel

08/14/2025 7:50 AM
Deep Track Capital, LP (1856083) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
08/14/2025 7:25 AM
Zura Bio (1855644) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2025 7:20 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/16/2025 8:34 AM
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
JPMORGAN CHASE & CO (19617) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G
07/01/2025 6:47 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2025 5:30 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2025 8:38 PM
Becker Daniel J. (1752139) Reporting
Zura Bio (1855644) Issuer
Form 3
Initial statement of beneficial ownership of securities  
05/29/2025 8:39 PM
Becker Daniel J. (1752139) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/28/2025 4:28 PM
AI Biotechnology LLC (1942670) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13D
05/27/2025 5:45 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/23/2025 8:20 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/22/2025 4:37 PM
Munshi Amit (1612551) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:38 PM
Sidhu Someit (1870329) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:39 PM
Ploos van Amstel Arnout (1870330) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:33 PM
Jarrett Jennifer (1671311) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:34 PM
Graham Neil Murray Hamilton (1952700) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:35 PM
Schoch Steven J (1867508) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/22/2025 4:36 PM
Kulkarni Sandeep Chidambar (1945691) Reporting
Zura Bio (1855644) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2025 5:35 AM
Zura Bio (1855644) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025 4:43 PM
Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by
Zura Bio (1855644) Subject
Form SCHEDULE 13G/A
(Data available from 1/1/2016 forward)

Zura Bio SEC Filings - Frequently Asked Questions

Zura Bio (ZURA) has submitted 299+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

Zura Bio's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 12, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:ZURA) was last updated on 5/14/2026 by MarketBeat.com Staff.
From Our Partners